## Patient dies in Biogen MS drug trial

Mass High Tech: The Journal of New England Technology

In a Phase 2 clinical trial, Biogen Idec and Roche reported their multiple sclerosis treatment, ocrelizumab, showed signs of reducing the disease indications – but they also reported that one patient died during the testing.

The drug, developed for patients with relapsing-remitting multiple sclerosis, showed a reduction in the number of flare-ups in a year and a reduction in brain lesions.

SOURCE [1]

## Source URL (retrieved on 07/28/2014 - 6:30am):

http://www.mdtmag.com/news/2010/10/patient-dies-biogen-ms-drug-trial

## Links:

[1] http://www.masshightech.com/stories/2010/10/18/daily27-Patient-dies-in-Biogen-MS-drug-trial.html

Page 1 of 1